↑ トップへ ← 戻る

 Drug(薬物リスト) DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

34 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Azithromycin  10件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Po azithromycin; Study medication, azithromycin;   D02134
 D06390
 D07486 
 -   -   6件:
13,
84,
85,
96,
228,
299
 2   Aztreonam  8件: Aztreonam; Aztreonam for inhalation (ai); Aztreonam for inhalation solution (azli); Aztreonam lysine; Aztreonam lysine for inhalation; Aztreonam lysine for inhalation (azli); Nasal aztreonam; Oral aztreonam;   D00240
 D06558 
 -   -   2件:
228,
299
 3   Basiliximab  1件: Basiliximab;   D03058   1件: IL2RA   11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   7件:
2,
50,
65,
66,
97,
222,
228
 4   Bortezomib  6件: Bortezomib; Bortezomib (velcade®); Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Combination of a single dose anti-cd20 antibody and bortezomib; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab;   D03150   1件: PSMB5   1件: Proteasome   13件:
11,
26,
28,
46,
49,
51,
61,
63,
66,
228,
256,
288,
331
 5   Budesonide  39件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose of budesonide; Inhaled/swallowed budesonide; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide;   D00246   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   10件:
66,
85,
93,
94,
95,
96,
97,
98,
228,
299
 6   Chloride ion  -  -   -   -   17件:
6,
11,
13,
14,
34,
46,
51,
96,
97,
127,
168,
193,
227,
228,
288,
297,
299
 7   Cholecalciferol  9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3;   D00188   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   15件:
6,
13,
19,
20,
34,
46,
49,
53,
60,
65,
96,
97,
228,
298,
299
 8   Ciclosporin  4件: Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 9   Clarithromycin  6件: Biaxin ( clarithromycin); Clarithromycin; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Rifabutin, clarithromycin, and clofazimine; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication);   D00276   -   -   8件:
6,
63,
84,
96,
97,
222,
228,
299
 10   Erythromycin  2件: Erythromycin; Oral erythromycin;   D00140
 D00851
 D01361
 D02009
 D02184
 D02523
 D02524
 D02525
 D04054 
 -   -   5件:
6,
36,
164,
228,
291
 11   Etanercept  39件: 50 mg etanercept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg solution for injection; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);   D00742   2件: LTA, TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   15件:
15,
28,
35,
38,
39,
46,
50,
53,
56,
60,
85,
228,
271,
285,
298
 12   Ethanol  7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 13   Everolimus  6件: Afinitor (everolimus); Everolimus; Everolimus (rad001); Everolimus (rad001) , afinitor®; Rad001, everolimus; Rad001: everolimus;   D02714   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   9件:
34,
67,
89,
96,
137,
157,
158,
228,
277
 14   Fluticasone  5件: Flovent (fluticasone propionate); Fluticasone; Fluticasone mdi; Fluticasone propionate; Swallowed fluticasone;   D07981   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   4件:
98,
228,
299,
306
 15   Fluticasone propionate  2件: Flovent (fluticasone propionate); Fluticasone propionate;   D01708   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   4件:
98,
228,
299,
306
 16   Formoterol  4件: Budesonide-formoterol single inhaler; Budesonide/formoterol; Formoterol; Formoterol/budesonide;   D01373
 D05277
 D07990 
 1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
85,
228,
299,
306
 17   Helium  6件: Helium; Helium / oxygen mixed gas inhalation therapy; Helium-3; Hyperpolarized helium-3; Hyperpolarized helium-3 mri; Hyperpolarized helium-3 mri of the chest;   D04420   -   -   3件:
228,
299,
330
 18   Helium He-3  -  -   -   -   2件:
228,
299
 19   Interferon gamma-1b  2件: Interferon gamma-1b; Interferon gamma-1b (actimmune);   D00747   2件: IFNGR1, IFNGR2   19件: Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis   7件:
65,
85,
90,
228,
299,
301,
326
 20   Itacitinib  1件: Itacitinib;   D10944   1件: JAK1   26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   4件:
46,
60,
97,
228
 21   L-Lysine  2件: L-lysine; L-lysine-n-acetylcysteinate;   D02304   -   -   4件:
13,
97,
228,
299
 22   Lactose  3件: Lactose; Lactose in water; Lactose monohydrate;   D00046
 D03226 
 -   -   6件:
2,
6,
13,
97,
228,
310
 23   Montelukast  8件: 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium);   D00529
 D08229 
 1件: CYSLTR1   2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction   5件:
13,
46,
85,
98,
228
 24   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 25   Nintedanib  5件: L01xe31 - nintedanib; Nintedanib; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Sub-study: nintedanib;   D10481   8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB   34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway   4件:
51,
85,
89,
228
 26   Pirfenidone  5件: Pirfenidone; Pirfenidone 267 mg [esbriet]; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Sub-study: pirfenidone;   D01583   6件: CCL2, IL10, IL1A, IL1B, IL6, TNF   80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   10件:
34,
46,
50,
51,
58,
84,
85,
164,
222,
228
 27   Prednisone  57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone);   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 28   Ruxolitinib  1件: Ruxolitinib;   D09959   2件: JAK1, JAK2   32件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis   1件:
228
 29   Salbutamol  5件: Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet;   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   13件:
3,
11,
12,
13,
49,
85,
86,
89,
113,
228,
231,
256,
299
 30   Sodium chloride  14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution;   D02056   -   -   19件:
6,
11,
13,
14,
17,
34,
46,
51,
53,
67,
78,
86,
97,
168,
193,
227,
228,
288,
299
 31   Tacrolimus  13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate;   D00107
 D08556 
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 32   Vitamin D  16件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); High-dose vitamin d (2000 iu per day); Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Standard-dose vitamin d (400iu per day); Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d in arm b; Vitamin d oil; Vitamin d powder;   -   -   -   18件:
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299
 33   Xenon  7件: Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment; Hyperpolarized 129-xenon gas; Hyperpolarized xenon; Hyperpolarized xenon gas; Xenon; Xenon contrast agent; Xenon-129;   D01901
 D06339 
 -   -   5件:
22,
85,
228,
231,
299
 34   Xenon-133  -  -   -   -   5件:
22,
85,
228,
231,
299

先頭へ